Chronic Myeloid Leukemia - T-lymphocyte cell therapy - CD19 expression

Association details:

Biomarker:	CD19 expression
Cancer:	Chronic Myeloid Leukemia
Drug Class:	T-lymphocyte cell therapy
Direction:	Sensitive

Evidence:

Evidence Level:

Sensitive: D – Preclinical

Source:

Biomed Pharmacother

Title:

ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft

Published date:

02/04/2021

Excerpt:

The subcutaneous tumor models were constructed using human chronic myelogenous leukemia cells expressing CD19 (K562-CD19) and human prostate cancer cells expressing PSCA (PC3-PSCA), and treated with CD19/△PD-1 CAR-T and PSCA/△PD-1 CAR-T cells, respectively. The tumor volumes significantly reduced within one week, indicating the good tumor growth inhibitory effect of △PD-1 CAR-T cells. Mice injected with △PD-1 CAR-T cells showed a significantly prolonged survival time compared to those with normal CAR-T cells.

DOI:

10.1016/j.biopha.2021.111339